BeiGene Presents First Quarter 2024 Financial Results and Latest Business News
Total revenues of $752 million in the first quarter, including product revenues of $747 million, an increase of 82% from the prior year period BRUKINSA revenues of $489 million, driven by a growth in the United States and Europe of 153% and 243%, respectively, compared to the prior year period; with recent fifth FDA approval, BRUKINSA now has largest label in BTKi class Rapid advancement of late-stage hematology pipeline; sonrotoclax in development both as a monotherapy and in combination with the basic treatment BRUKINSA; launch of a pivotal program for BTK CDACs Advancement of potentially differentiated solid tumor programs with ADCs, degrader platforms and targeted therapies in priority cancer types Significant improvement in operating leverage and progress towards sustainable profitability
